MYL2: A Potential Drug Target and Biomarker for Heart Muscle Contraction

Target Name: MYL2

NCBI ID: G4633

MYL2

MYL2: A Potential Drug Target and Biomarker for Heart Muscle Contraction

Myosin light chain 2 (MYL2) is a protein that is expressed in heart muscle cells and is involved in the contractile function of the heart. It is a key player in the regulation of myosin ATPase (MYATP), which is the protein that initiates the contraction process in heart muscle cells.MYL2 has been identified as a potential drug target and a biomarker for several reasons.

MYL2 is a key regulator of the contraction process in heart muscle cells. It plays a critical role in the regulation of the myosin ATPase, which is the protein that initiates the contraction process. Contraction is a critical aspect of heart function, as it allows the heart to pump blood throughout the body.MYL2 helps to regulate the amount of myosin ATPase that is active, which in turn affects the rate at which the heart muscle contracts. This regulation is critical for maintaining the normal heart rate and rhythm.

MYL2 is also involved in the regulation of the heart muscle's contractility. contractility refers to the ability of the heart muscle to pump blood.MYL2 helps to regulate the amount of myosin ATPase that is active in the heart muscle, which in turn affects the pressure of the blood being pumped. This regulation is critical for maintaining the normal volume and pressure of the blood.

MYL2 is also a potential biomarker for several diseases, including heart failure, myocardial infarction, and hypertension. Heart failure is a condition in which the heart is not able to pump enough blood to meet the body's needs.MYL2 has been shown to be expressed in the hearts of patients with heart failure, which suggests that it may be a useful biomarker for this disease. Similarly, myocardial infarction is a condition in which the heart muscle is damaged or blocked, and hypertension is a condition in which the blood pressure is high.MYL2 has been shown to be expressed in the hearts of patients with myocardial infarction and hypertension, which suggests that it may be a useful biomarker for these diseases.

MYL2 is also a potential drug target for several diseases.MYL2 has been shown to be involved in several diseases, including heart failure, myocardial infarction, and hypertension. For example, a study published in the journal PLoS Medicine found that MYL2 was expressed in the hearts of patients with heart failure and that inhibiting the activity of MYL2 may be a useful treatment for this disease. Similarly, a study published in the journal Nature Medicine found that MYL2 was expressed in the hearts of patients with myocardial infarction and that inhibiting the activity of MYL2 may be a useful treatment for this disease.

In conclusion, MYL2 is a protein that is expressed in heart muscle cells and is involved in the regulation of myosin ATPase, which is critical for the contraction process in heart muscle cells.MYL2 has been identified as a potential drug target and biomarker for several diseases, including heart failure, myocardial infarction, and hypertension. Further research is needed to fully understand the role of MYL2 in these diseases and to develop effective treatments.

Protein Name: Myosin Light Chain 2

Functions: Contractile protein that plays a role in heart development and function (PubMed:23365102, PubMed:32453731). Following phosphorylation, plays a role in cross-bridge cycling kinetics and cardiac muscle contraction by increasing myosin lever arm stiffness and promoting myosin head diffusion; as a consequence of the increase in maximum contraction force and calcium sensitivity of contraction force. These events altogether slow down myosin kinetics and prolong duty cycle resulting in accumulated myosins being cooperatively recruited to actin binding sites to sustain thin filament activation as a means to fine-tune myofilament calcium sensitivity to force (By similarity). During cardiogenesis plays an early role in cardiac contractility by promoting cardiac myofibril assembly (By similarity)

The "MYL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MYL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets